Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Netropsin is a pyrrole-amidine natural product antibiotic originally isolated from *Streptomyces netropsis*. It is a classic example of a DNA minor groove binder, exhibiting high affinity for AT-rich sequences. By occupying the minor groove, netropsin physically blocks the binding of various DNA-binding proteins, including the High-mobility group AT-hook 2 (HMGA2) transcription factor. Research indicates that by inhibiting HMGA2-DNA interactions, netropsin can suppress the epithelial-mesenchymal transition (EMT) in melanoma cells, particularly those with BRAF mutations, thereby reducing metastasis and migratory behavior. Although it possesses potent antibacterial and antiviral activities, its clinical utility has been limited by systemic toxicity, and it is currently utilized primarily as a biochemical research tool for studying DNA-protein interactions and as a lead compound for developing sequence-specific DNA binders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on netropsin.